Talkspace (TALK) 10-Q 5 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 02, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Registrant Name	TALKSPACE, INC.
Entity Central Index Key	0001803901
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		155,116,870
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-39314
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-4636604
City Area Code	212
Local Phone Number	284-7206
Document Quarterly Report	true
Document Transition Report	false
Common stock
Document Information [Line Items]
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	TALK
Security Exchange Name	NASDAQ
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase common stock
Trading Symbol	TALKW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 184,127	$ 198,256
Accounts receivable, net of reserves of $4,706 and $4,918 as of March 31, 2022 and December 31, 2021, respectively	6,312	5,512
Other current assets	5,039	9,562
Total current assets	195,478	213,330
Property and equipment, net	633	624
Intangible assets, net	3,086	3,436
Goodwill	6,134	6,134
Other long-term assets	82	82
Total assets	205,413	223,606
CURRENT LIABILITIES:
Accounts payable	9,490	7,429
Deferred revenues	6,026	7,186
Accrued expenses and other current liabilities	10,234	12,562
Total current liabilities	25,750	27,177
Warrant liabilities	3,195	4,070
Other long-term liabilities	191	86
Total liabilities	29,136	31,333
Commitments and contingencies (Note 7)
STOCKHOLDERS' DEFICIT:
Common stock of 0.0001 par value - Authoriszed: 1,000,000,000 shares at March 31, 2022 and December 31, 2021; Issued and outstanding: 155,104,655 and 152,862,447 shares at March 31, 2022 and December 31, 2021, respectively	15	15
Additional paid-in capital	368,152	363,788
Accumulated deficit	(191,890)	(171,530)
Total stockholders' equity	176,277	192,273
Total liabilities and stockholders' equity	$ 205,413	$ 223,606

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Allowance, Accounts Receivable	$ 4,706	$ 4,918
Restricted Cash	$ 400
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	155,104,655	152,862,447
Common stock, shares outstanding	155,104,655	152,862,447

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Revenue		$ 30,150	$ 27,157
Cost of revenues		15,129	9,814
Gross profit		15,021	17,343
Operating expenses:
Research and development, net		5,035	2,964
Clinical operations		1,776	2,077
Sales and marketing		21,408	22,251
General and administrative		8,010	2,608
Total operating expenses		36,229	29,900
Operating loss		21,208	12,557
Financial (income) expense, net		869	(173)
Loss before taxes on income		20,339	12,730
Taxes on income		21	8
Net Loss		$ 20,360	$ 12,738
Net loss per share (1):
Basic and diluted net loss per share	[1]	$ 0.13	$ 0.93
Weighted average number of common shares (1):
Weighted average number of common shares used in computing basic and diluted net loss per share:	[1]	154,083,443	13,762,205
[1]	Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Operations and Comprehensive Loss (Parenthetical)	1 Months Ended
	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Common stock, conversion ratio	1.134140

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands		Total	Convertible Preferred Stock	Common stock		Additional Paid-in Capital		Accumulated Deficit
Beginning balance, value at Dec. 31, 2020	[1]		$ 111,282
Beginning balance, shares at Dec. 31, 2020	[1]		94,582,550
Beginning balance, value at Dec. 31, 2020		$ (98,898)		$ 1	[1]	$ 9,889	[1]	$ (108,788)
Beginning balance, shares at Dec. 31, 2020	[1]			13,413,431
Exercise of stock options		797				797	[1]
Exercise of stock options, share	[1]			684,923
Stock-based compensation		1,513				1,513	[1]
Issuance of warrants		125				125	[1]
Net loss		(12,738)						(12,738)
Ending balance, value at Mar. 31, 2021	[1]		$ 111,282
Ending balance, shares at Mar. 31, 2021	[1]		94,582,550
Ending balance, value at Mar. 31, 2021		(109,201)		$ 1	[1]	12,324	[1]	(121,526)
Ending balance, shares at Mar. 31, 2021	[1]			14,098,354
Beginning balance, value at Dec. 31, 2021			$ 0
Beginning balance, shares at Dec. 31, 2021			0
Beginning balance, value at Dec. 31, 2021		$ 192,273		$ 15		363,788		(171,530)
Beginning balance, shares at Dec. 31, 2021		152,862,447		152,862,447
Exercise of stock options		$ 2,063				2,063
Exercise of stock options, share		2,164,870		2,164,870
Restricted Stock Units Vested		$ (67)				(67)
Restricted Stock Units Vested Shares				77,338
Stock-based compensation		2,368				2,368
Net loss		(20,360)						(20,360)
Ending balance, value at Mar. 31, 2022			$ 0
Ending balance, shares at Mar. 31, 2022			0
Ending balance, value at Mar. 31, 2022		$ 176,277		$ 15		$ 368,152		$ (191,890)
Ending balance, shares at Mar. 31, 2022		155,104,655		155,104,655
[1]	Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Parenthetical)	1 Months Ended
	Jun. 30, 2021
Statement of Stockholders' Equity [Abstract]
Common stock, conversion ratio	1.134140

Condensed Consolidated Statem_5

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss		$ (20,360)	$ (12,738)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		429	462
Stock-based compensation		2,368	1,513
Warrant change in fair value		(875)	165
Increase in accounts receivable		(800)	(1,666)
Decrease (increase) in other current assets		4,923	(1,076)
Increase in accounts payable		2,061	7,030
(Decrease) increase in deferred revenues		1,160	(2,878)
Decrease in accrued expenses and other current liabilities		(1,837)	(447)
Increase in other long-term liabilities		105	0
Net cash used in operating activities		(15,146)	(3,879)
Cash flows from investing activities:
Purchase of property and equipment		(88)	(319)
Net cash used in investing activities		(88)	(319)
Cash flows from financing activities:
Payment of deferred issuance costs		0	75
Proceeds from exercise of stock options		2,063	797
Payments for employee taxes withheld related to vested stock-based awards		558	0
Net cash provided by financing activities		1,505	722
Net decrease in cash and cash equivalents		(13,729)	(3,476)
Cash and cash equivalents at the beginning of the period		198,256	13,248
Cash and cash equivalents at the end of the period	[1]	184,527	9,772
Supplemental cash flow data:
Cash paid during the period for interest		12	5
Cash paid during the period for income taxes		174
Non-Cash financing activities:
Deferred issuance costs		0	2,673
Issuance of warrant and other costs related to the Credit Agreement		$ 0	$ 175
[1]	As of March 31, 2022, amount includes restricted cash of $ 0.4 million maintained in a short-term certificate of deposit account and included within other current assets in the condensed consolidated balance sheet.

Condensed Consolidated Statem_6

Condensed Consolidated Statement of Cash Flows (Parenthetical) $ in Millions	Mar. 31, 2022USD ($)
Statement of Cash Flows [Abstract]
Restricted Cash	$ 0.4

Description of Organization and

Description of Organization and Business Operations	3 Months Ended
	Mar. 31, 2022
Description Of Organisation And Business Operation [Abstract]
Description of organization and business operations	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Talkspace, Inc. (together with its consolidated subsidiaries, the “Company” or “Talkspace”) is a leading behavioral healthcare company enabled by a purpose-built technology platform. Talkspace provides individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Talkspace was originally incorporated as Hudson Executive Investment Corp. (“HEC”). In connection with the Business Combination completed in June 2021, HEC filed the Certificate of Incorporation and changed its name to “Talkspace, Inc.”. Operating Segments The Company operates its business as a single segment and as one reporting unit, which is how our chief operating decision maker (who is our interim chief executive officer) reviews financial performance and allocates resources.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2. SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2021, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Use of estimates The preparation of consolidated financial statements, in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Recently Issued and Adopted Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of t he guidance is permitted. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this guidance on January 1, 2022 and the adoption did not have a significant impact on its condensed consolidated financial statements or related disclosures. In May 2021, the FASB issued ASU 2021-04—Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in accounting for modifications or exchanges of freestanding equity-written call options that remain equity classified after modifications or exchanges based on the substance of the transactions. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures. In August 2020, the FASB issued ASU 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer's Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments in this ASU are effective for public entities excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	NOTE 3. REVENUE RECOGNITION The Company is operating a virtual behavioral healthcare business that connects individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Individuals access the Company’s services through the Company’s website or mobile app. The Company generates revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to its therapy platform as well as supplementary a la carte offerings, payments from members and their respective insurance companies and annually contracted platform access fees from enterprise clients for the delivery of therapy services to their members or employees. The Company provides these services directly to individuals through a subscription plan. The Company also contracts with health plans and other enterprises to provide its services to individuals who are qualified to receive access to the Company’s services through the Company’s commercial arrangements. The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended March 31, (in thousands) 2022 2021 Revenues from sales to unaffiliated customers:   Consumers $ 17,260 $ 18,564 Commercial 12,890 8,593 Total $ 30,150 $ 27,157 Accounts Receivable and Revenue Reserves Revenue reserves are deducted from accounts receivable to present the net amount expected to be collected. As of March 31, 2022, revenue reserves mainly relate to allowances for accounts receivable balances from health insurance and EAP organizations. During the three months ended March 31, 2022 , the Company recorded an increase in revenue reserves of $ 1.0 million. During the three months ended March 31, 2022 , the Company also wrote-off $ 1.2 million of aged receivables that were previously fully reserved. As of March 31, 2022, the balance of receivables related to health insurance and EAP organization s was $ 6.0 million an d the revenue reserves against these receivables was $ 4.7 million, of this amount $ 3.4 million relates to aged balances for periods prior to 2022. Deferred Revenue The Company records deferred revenue when cash payments are received in advance of the Company’s performance obligation to provide services. As of March 31, 2021, deferred revenue related mainly to the Company’s consumer subscription business. D eferred revenue as of March 31, 2022 was $ 6.0 million ( $ 7.2 million as of December 31, 2021). The Company recognizes deferred revenues as revenues in the statement of operations once performance obligations have been performed and satisfied. The Company expects to satisfy the majority of its performance obligations associated with deferred revenue within one year or less. Contract Costs The Company elected to use the practical expedient to recognize the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 4. FAIR VALUE MEASUREMENT The carrying value of the Company’s cash equivalents, accounts receivable, other current assets, accounts payable, and accrued liabilities approximate fair value because of the relatively short-term nature of the underlying assets. The Company’s Private Placement Warrants are carried at fair value with changes in fair value recognized in earnings each period. The Private Placement Warrants acquired in connection with the consummation of the Business Combination and the closing of the Forward Purchase Agreement with the HEC Fund are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within financial (income) expense, net in the condensed consolidated statement of operations. The Private Placement Warrants were valued using the Black-Scholes-Merton Model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the Company’s common stock. The expected volatility of the Company’s common stock was estimated to be approximately 68.8 % and 67.8 % as of March 31, 2022 and December 31, 2021, respectively. For the three months ended March 31, 2022, the Company had gains related to the revaluation of the Private Placement Warrants of $ 0.9 million. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at March 31, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: (in thousands) Level March 31, 2022 December 31, 2021 Liabilities: (unaudited) Warrant liability – Private Placement Warrants 3 $ 3,195 $ 4,070 The following table presents the changes in the fair value of warrant liabilities during the three months ended March 31, 2022: (in thousands) Private Placement Balance at December 31, 2021 $ 4,070 Change in value ( 875 ) Balance at March 31, 2022 (unaudited) $ 3,195 In connection with the consummation of the Business Combination, the Company also acquired Public Warrants from HEC and also issued equity warrants to certain consultants. The Company determined these warrants met the criteria to be classified as equity in accordance with ASC 815-40. The Company valued these warrants using the instrument’s publicly listed trading price on the date of acquisition or issuance, where applicable, and included in additional paid-in capital within stockholder’s deficit. This is considered to be a non-recurring Level 1 measurement due to the use of an observable market quote in an active market.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 5. COMMITMENTS AND CONTINGENT LIABILITIES Lease commitments The Company does not currently have any leases with terms in excess of 12 months. Since terminating our prior office lease in New York City in August 2020, the Company has an immaterial short-term sublease for office space in New York City. The Company currently has no permanent physical office space and the majority of our employees are working remotely. The Company has limited operations outside the United States. The Company has one foreign subsidiary located in Israel which leases its operating facilities under a month-to-month operating lease agreement. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition, but recognizes lease expenses over the lease term on a straight-line basis. The Company also elected the practical expedient to not separate lease and non-lease components for all of the Company’s leases. Rent expenses under the Company’s short-term operating leases for the three months ended March 31, 2022 was $ 0.1 million (insignificant for the three months ended March 31, 2021). Litigation The Company is and may in the future be involved in various legal proceedings arising from the normal course of business activities. Although the results of litigation and claims cannot be predicted with certainty, currently, the Company believes that the likelihood of any material adverse impact on the Company’s consolidated results of operations, cash flows or our financial position for any such litigation or claims is remote. Regardless of the outcome, litigation can have an adverse impact on the Company because of the costs to defend lawsuits, diversion of management resources and other factors. In January 2022, the Company and certain of its current and former officers and directors were named as defendants in a soon to be consolidated securities class action complaint currently listed in the United States District Court for the Southern District of New York (the “Securities Actions”) under the case headings: (1) Baron v. Talkspace et al., No. 22-cv-00163 (S.D.N.Y.) and (2) Valdez v. Talkspace et al., No. 22-cv-00840 (S.D.N.Y.). The Securities Actions asserted violations of sections 10(b), 14(a) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder. The Securities Actions generally relate to public disclosures and statements by the Company in connection with the Business Combination. The complaints seek, among other things, damages on behalf of all members of the proposed class. The Court is currently considering a lead plaintiff(s) for the consolidated case. The Company is not able to predict the outcome of these lawsuits, nor can it predict the amount of time and expense that will be required to resolve the lawsuits. The Company believes that the lawsuits are without merit and intends to vigorously defend against them. In addition to the foregoing, from time-to-time, the Company is party to various legal proceedings, claims and litigation that arise in the normal course of business. In the opinion of management, the ultimate outcome of these matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated. Warranties and Indemnification The Company’s arrangements generally include certain provisions for indemnifying clients against liabilities if there is a breach of a Client’s data or if the Company’s service infringes a third party’s intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by the Company, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions.

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Capital Stock	NOTE 6. CAPITAL STOCK The Company’s authorized capital stock consists of (a) 1,000,000,000 shares of common stock, par value $ 0.0001 per share; and (b) 100,000,000 shares of preferred stock, par value $ 0.0001 per share. As of March 31, 2022, there were 155,104,655 shares of common stock issued and outstanding ( 152,862,447 as of December 31, 2021). As of March 31, 2022 and December 31, 2021, there were no shares of preferred stock issued or outstanding.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	NOTE 7. SHARE-BASED COMPENSATION The Company adopted the 2014 Stock Incentive Plan (the “2014 Plan”) pursuant to which incentive and nonqualified stock options and stock purchase rights to purchase the Company’s common stock may be granted to officers, employees, directors, consultants and service providers. In connection with the closing of the Business Combination, the Company adopted the 2021 Incentive Award Plan (the “2021 Plan”) under which the Company may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent. In connection with the effectiveness of the 2021 Plan, no further awards will be granted under the 2014 Plan. Employees, consultants and directors of the Company, and employees and consultants of its subsidiaries, are eligible to receive awards under the 2021 Plan. The 2021 Plan is administered by the Company’s board of directors, which may delegate its duties and responsibilities to one or more committees of the Company’s directors and/or officers (referred to collectively as the “plan administrator”), subject to the limitations imposed under the 2021 Plan, Section 16 of the Securities Exchange Act of 1934, as amended, stock exchange rules and other applicable laws. The plan administrator has the authority to take all actions and make all determinations under the 2021 Plan, to interpret the 2021 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2021 Plan as it deems advisable. The plan administrator also has the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the 2021 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2021 Plan. The maximum number of shares of Talkspace common stock that may be issued pursuant to the exercise of incentive stock options granted under the 2021 Plan is 100,000,000 . The aggregate share limit under the 2021 Plan will be subject to an annual increase on the first day of each calendar year beginning January 1, 2022 and ending on and including January 1, 2031 by a number of shares equal to the lesser of (i) a number equal to 5 % of the aggregate number of shares of Talkspace common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Talkspace common stock as is determined by the Talkspace board of directors. An a ggregate of 11,995,601 shares of Talkspace common stock are available for issuance under the 2021 Plan as of March 31, 2022. In connection with the closing of the Business Combination, the Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”) under which employees of Talkspace and its participating subsidiaries are provided with the opportunity to purchase Talkspace common stock at a discount through accumulated payroll deductions during successive offering periods. The 2021 ESPP is administered by the compensation committee of the Company’s board of directors (referred to collectively as the “plan administrator”). The plan administrator has the authority to take all actions and make all determinations under the 2021 ESPP, to interpret the 2021 ESPP and to adopt, amend and repeal rules for the administration of the 2021 ESPP as it deems advisable. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2022 and ending in 2031, by an amount equal to the lesser of (i) 1 % of the aggregate number of shares of Talkspace common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Talkspace common stock as determined by the Talkspace board of directors. The maximum number of shares of Talkspace common stock that may be granted under the 2021 ESPP is 50,000,000 . An aggregate of 4,573,602 shares of Talkspace common stock are available for issuance under the 2021 ESPP as of March 31, 2022. All stock-based awards are measured based on the grant date fair value and are generally recognized on a straight-line basis in the Company’s condensed consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period). Stock Options Stock options issued under the Plans generally vest over a four-year period and are exercisable a maximum period of ten years. A summary of the Company’s stock option activity under the 2014 Plan and the 2021 Plan for the three months ended March 31, 2022 is as follows: Three Months Ended March 31, 2022 Number of Weighted Weighted Aggregate (1) (in thousands) Outstanding at the beginning of the period 19,494,202 $ 1.95 6.88 $ 19,214 Granted 1,552,395 $ 1.61 Exercised ( 2,164,870 ) $ 0.95 Forfeited ( 426,122 ) $ 5.06 Outstanding at the end of the period 18,455,605 $ 1.97 7.15 $ 14,220 Exercisable at the end of the period 13,432,414 $ 0.86 5.92 $ 13,623 (1) The agg regate intrinsic value of options outstanding and options exercisable at end of the period does not include 4,779,271 and 1,366,014 options that are out of the money, respectively. The weighted average grant-date fair value of stock options granted to employees during the three months ended March 31, 2022 and 2021 was $ 1.06 and $ 7.00 , respectively. As of March 31, 2022, there was $ 16.2 million of total unrecognized compensation cost related to non-vested options that are expected to be recognized over a period of up to 4 years . Restricted Stock Units The Company began issuing restricted stock units (“RSUs”) to certain employees and directors of the Company in the fourth quarter of 2021 under the 2021 plan. These RSUs typically vest over a four-year period. The following table summarizes the activity for RSUs for the three months ended March 31, 2022: Three months ended March 31, 2022 Number of Weighted Nonvested at beginning of the period 2,330,094 $ 3.58 Granted 3,452,961 $ 1.61 Vested ( 116,613 ) $ 3.58 Forfeited ( 215,518 ) $ 3.33 Nonvested at end of the period 5,450,924 $ 2.35 The fair value as of the respective vesting dates of RSUs that vested during three months ended March 31, 2022 was $ 0.2 million. As of March 31, 2022, there was $ 12.4 million of total unrecognized compensation cost related to non-vested RSUs that are expected to be recognized over a period of u p to 3.9 years. The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations: Three Months Ended March 31, (in thousands) 2022 2021 Research and development, net $ 546 $ 172 Clinical Operations 122 71 Sales and Marketing 777 877 General and administrative 923 393 Total stock-based compensation expense $ 2,368 $ 1,513

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	NOTE 8. NET LOSS PER SHARE The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended March 31, (in thousands, except share and per share data) 2022 2021 Net loss $ 20,360 $ 12,738 Weighted-average shares used to compute net loss per share, (1) 154,083,443 13,762,205 Net loss per share, basic and diluted (1) $ 0.13 $ 0.93 (1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination. For the three months ended March 31, 2022 , t he following were excluded from the calculation of diluted income per share since each would have had an anti-dilutive effect given the Company ’ s net loss: 18,455,605 stock options, 5,450,924 restricted stock units, 12,780,000 private placement warrants and 21,350,000 public warrants to purchase the Company’s common stock. For the three months ended March 31, 2021, the following were excluded from the calculation of diluted loss per share since each would have had an anti-dilutive effect given the Company’s net loss: 94,582,550 shares of convertible preferred stock, 20,631,735 stock options, 60,000 warrants to the Company ’ s common stock and 50,881 warrants to the Company ’ s series D convertible preferred stock.

Taxes on Income

Taxes on Income	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Taxes on Income	NOTE 9. TAXES ON INCOME As a result of the Company’s history of net operating losses (“NOL”), the Company has provided for a full valuation allowance against its deferred tax assets for assets that are not expected to be realized. The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities Abstract
Accrued Expenses and Other Current Liabilities	NOTE 10. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities are comprised of the following: (in thousands) March 31, 2022 December 31, 2021 Employee compensation $ 3,135 $ 5,988 User acquisition 2,791 2,680 Professional fees 1,096 1,303 Other 3,212 2,591 Accrued expenses and other current liabilities $ 10,234 $ 12,562

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Event	NOTE 11. SUBSEQUENT EVENTS The Company ’ s wholly owned subsidiaries, Talkspace LLC and Talkspace Network LLC are in the process of entering into various management service agreements (“MSAs”) with Talkspace Provider Network, PA (“TPN”), a Texas professional association entity, a s part of the transition of the Company’s structure with respect to its relationships with healthcare providers in response to its expansion of service offerings to include telepsychiatry services provided through licensed physicians. TPN is then contracting with the Company’s affiliated professional entities and physicians, therapists, and other licensed professionals for clinical and professional services provided to the Company’s members. The Company believes the transition to a structure where it operates under various MSAs with TPN, or an entity authorized by state law to contract with our affiliated professionals to delivery teletherapy services to our members, will better ensure the Company is able to comply with additional regulatory requirements, including the corporate practice of medicine and fee-splitting laws, that are necessarily implicated by engaging in telehealth care that can only be delivered by physicians. In April 2022, the Company transitioned its provider network to TPN. The Company is continuing to transition its current agreements with its clients, members and other business partners to TPN or an affiliated professional entity, where applicable. TPN is wholly-owned by an independent Texas-licensed physician. The Company has the power to direct the activities of TPN and the other authorized entities in each state that most significantly impact TPN’s and such other authorized entities’ economic performance as well as have the obligation to absorb significant losses and receive the benefits of TPN and the authorized entities. T he Company does not believe this transition will have a material financial impact on its operations.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2021, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Use of estimates	Use of estimates The preparation of consolidated financial statements, in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of t he guidance is permitted. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this guidance on January 1, 2022 and the adoption did not have a significant impact on its condensed consolidated financial statements or related disclosures. In May 2021, the FASB issued ASU 2021-04—Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in accounting for modifications or exchanges of freestanding equity-written call options that remain equity classified after modifications or exchanges based on the substance of the transactions. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures. In August 2020, the FASB issued ASU 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer's Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments in this ASU are effective for public entities excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue by Revenue Source	The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended March 31, (in thousands) 2022 2021 Revenues from sales to unaffiliated customers:   Consumers $ 17,260 $ 18,564 Commercial 12,890 8,593 Total $ 30,150 $ 27,157

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Fair Value Measurements	The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at March 31, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: (in thousands) Level March 31, 2022 December 31, 2021 Liabilities: (unaudited) Warrant liability – Private Placement Warrants 3 $ 3,195 $ 4,070
Summary of warrants	The following table presents the changes in the fair value of warrant liabilities during the three months ended March 31, 2022: (in thousands) Private Placement Balance at December 31, 2021 $ 4,070 Change in value ( 875 ) Balance at March 31, 2022 (unaudited) $ 3,195

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity under 2014 Plan and 2021 Plan	Three Months Ended March 31, 2022 Number of Weighted Weighted Aggregate (1) (in thousands) Outstanding at the beginning of the period 19,494,202 $ 1.95 6.88 $ 19,214 Granted 1,552,395 $ 1.61 Exercised ( 2,164,870 ) $ 0.95 Forfeited ( 426,122 ) $ 5.06 Outstanding at the end of the period 18,455,605 $ 1.97 7.15 $ 14,220 Exercisable at the end of the period 13,432,414 $ 0.86 5.92 $ 13,623
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	The following table summarizes the activity for RSUs for the three months ended March 31, 2022: Three months ended March 31, 2022 Number of Weighted Nonvested at beginning of the period 2,330,094 $ 3.58 Granted 3,452,961 $ 1.61 Vested ( 116,613 ) $ 3.58 Forfeited ( 215,518 ) $ 3.33 Nonvested at end of the period 5,450,924 $ 2.35
Summary of Stock-Based Compensation Expense	The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations: Three Months Ended March 31, (in thousands) 2022 2021 Research and development, net $ 546 $ 172 Clinical Operations 122 71 Sales and Marketing 777 877 General and administrative 923 393 Total stock-based compensation expense $ 2,368 $ 1,513

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended March 31, (in thousands, except share and per share data) 2022 2021 Net loss $ 20,360 $ 12,738 Weighted-average shares used to compute net loss per share, (1) 154,083,443 13,762,205 Net loss per share, basic and diluted (1) $ 0.13 $ 0.93 (1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination. For the three months ended March 31, 2022 , t

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities Abstract
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities are comprised of the following: (in thousands) March 31, 2022 December 31, 2021 Employee compensation $ 3,135 $ 5,988 User acquisition 2,791 2,680 Professional fees 1,096 1,303 Other 3,212 2,591 Accrued expenses and other current liabilities $ 10,234 $ 12,562

Business Combination - Addition

Business Combination - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Jun. 22, 2021	Mar. 31, 2021	[1]	Dec. 31, 2020	[1]
Business Acquisition [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, par value	$ 0.0001
Conversion of stock, conversion rate			$ 1.134140
Common stock, shares authorized	1,000,000,000	1,000,000,000
Preferred stock, shares authorized	100,000,000
Common stock, shares outstanding	155,104,655	152,862,447
Warrant liabilities	$ 3,195	$ 4,070
Common stock
Business Acquisition [Line Items]
Common stock, shares outstanding	155,104,655	152,862,447		14,098,354		13,413,431
[1]	Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregation of Revenue by Revenue Source (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues fom sales to unaffiliated customers:
Total Revenue	$ 30,150	$ 27,157
Consumer
Revenues fom sales to unaffiliated customers:
Total Revenue	17,260	18,564
Commercial
Revenues fom sales to unaffiliated customers:
Total Revenue	$ 12,890	$ 8,593

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Deferred Revenue	$ 6,000	$ 7,200
Increase In Revenue Reserve	1,000
Accounts receivable, net	6,312	$ 5,512
Aged receivables wrote-off	1,200
Revenue Reserves	4,700
Aged Balances	3,400
Health Plans and EAP Customers
Disaggregation of Revenue [Line Items]
Accounts receivable, net	$ 6,000

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - Private Placement Warrants - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Expected volatility	68.80%	67.80%
Gains on Revaluation of Warrants	$ 0.9

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Fair Value Measurements (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Private Placement Warrants
Liabilities:
Warrant Liability	$ 3,195	$ 4,070

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of warrants (Detail) - Private Placement Warrants $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Class of Warrant or Right [Line Items]
Fair value as of beginning	$ 4,070
Change in value	(875)
Fair value as of ending	$ 3,195

Borrowing Arrangements - Additi

Borrowing Arrangements - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Debt Instrument [Line Items]
Adjustments to additional paid in capital warrant issued	$ 125

Commitments and Contingent Li_2

Commitments and Contingent Liabilities - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Rental Expense	$ 0.1

Capital Stock - Additional Info

Capital Stock - Additional Information (Details) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000,000
Preferred stock, par value	$ 0.0001
Common Stock Shares Issued	155,104,655	152,862,447
Common stock, shares outstanding	155,104,655	152,862,447
Preferred Stock Shares Issued	0	0
Preferred stock, shares outstanding	0	0

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of stock options, share	2,164,870
Total unrecognized compensation cost, non-vested options	$ 16,200
Total unrecognized compensation cost non-vested options to be recognized, period	4 years
Share based compensation expense	$ 2,368	$ 1,513
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	$ 1.06	$ 7
Number of shares excluded from aggregate intrinsic value of options outstanding	4,779,271
Number of Shares excluded from Options Exercisable Aggregate Intrinsic Value	1,366,014
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	$ 1.61
Fair value of vested RSUs	$ 200
Total unrecognized compensation cost, non-vested options	$ 12,400
Total unrecognized compensation cost non-vested options to be recognized, period	3 years 10 months 24 days
2021 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for issuance	11,995,601
Maximum [Member] | 2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum increase in annual amount number of common stock shares outstanding percentage	1.00%
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of stock options, share	2,164,870	684,923	[1]
Common stock | 2021 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares to be issued in connection with stock option exercises under plan	100,000,000
Common stock | 2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for issuance	4,573,602
Common stock | Maximum [Member] | 2021 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum increase in annual amount number of common stock shares outstanding percentage	5.00%
Common stock | Maximum [Member] | 2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares granted	50,000,000
[1]	Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Option Activity under 2014 Plan and 2021 Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement, Disclosure [Abstract]
Number of options, Outstanding at the beginning of the period		19,494,202
Granted		1,552,395
Number of options, Exercised		(2,164,870)
Number of options, Forfeited		(426,122)
Number of options, Outstanding at the end of the period		18,455,605	19,494,202
Number of options, Exercisable at the end of the period		13,432,414
Weighted average exercise price, Outstanding at the beginning of the period		$ 1.95
Weighted average exercise price, Granted		1.61
Weighted average exercise price, Exercised		0.95
Weighted average exercise price, Forfeited		5.06
Weighted average exercise price, Outstanding at the end of the period		1.97	$ 1.95
Weighted average exercise price, Exercisable at the end of the period		$ 0.86
Weighted average remaining contractual term (in years)		7 years 1 month 24 days	6 years 10 months 17 days
Weighted average remaining contractual term (in years) Exercisable at the end of the period		5 years 11 months 1 day
Aggregate intrinsic value, Outstanding	[1]	$ 14,220	$ 19,214
Aggregate intrinsic value, Exercisable at the end of the period	[1]	$ 13,623
[1]	The agg regate intrinsic value of options outstanding and options exercisable at end of the period does not include 4,779,271 and 1,366,014 options that are out of the money, respectively.

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Option Activity under 2014 Plan and 2021 Plan (Parenthetical) (Detail)	Jun. 22, 2021$ / shares
Share-based Payment Arrangement, Disclosure [Abstract]
Conversion of stock, conversion rate	$ 1.134140

SHARE-BASED COMPENSATION - Su_3

SHARE-BASED COMPENSATION - Summary of Stock Option Activity Under Restricted Stock Units (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	1,552,395
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance	2,330,094
Granted	3,452,961
Vested	116,613
Forfeited	215,518
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance	5,450,924
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 3.58
Granted | $ / shares	1.61
Vested | $ / shares	3.58
Forfeited | $ / shares	3.33
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance | $ / shares	$ 2.35

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	$ 2,368	$ 1,513
Research and Development, net
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	546	172
Clinical Operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	122	71
Sales and Marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	777	877
General and Administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	$ 923	$ 393

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss		$ 20,360	$ 12,738
Denominator:
Weighted average number of common shares used in computing basic and diluted net loss per share:	[1]	154,083,443	13,762,205
Net loss per share, basic and diluted	[1]	$ 0.13	$ 0.93
[1]	Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in June 2021 as a result of the Business Combination.

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	5,450,924
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share		94,582,550
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	18,455,605	20,631,735
Private Placement Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	12,780,000
Public Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	21,350,000
Warrants To Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share		60,000
Warrant to Purchase Series D Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share		50,881

Net Income (Loss) Per Share -_2

Net Income (Loss) Per Share - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Parenthetical) (Detail)	Jun. 22, 2021$ / shares
Earnings Per Share [Abstract]
Conversion of stock, conversion rate	$ 1.134140

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued Expense and Other Current Liabilities [Abstract]
Employee compensation	$ 3,135	$ 5,988
User acquisition	2,791	2,680
Professional fees	1,096	1,303
Other	3,212	2,591
Accrued expenses and other current liabilities	$ 10,234	$ 12,562